Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Development of Kinase Chemogenomic Set Reaches Milestone

Investigators at the University of North Carolina at Chapel Hill Structural Genomics Consortium (SGC-UNC)—in partnership with the DiscoverX Corporation—have reached the halfway point in their development of a potent group of inhibitors which allow deeper explo

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Investigators at the University of North Carolina at Chapel Hill Structural Genomics Consortium (SGC-UNC)—in partnership with the DiscoverX Corporation—have reached the halfway point in their development of a potent group of inhibitors which allow deeper exploration of the human kinome, dubbed the Kinase Chemogenomic Set. Findings from the new study—published recently in PLOS ONE through an article entitled “Progress towards a public chemogenomic set for protein kinases and a call for contributions”— should help the scientific community better understand the role the kinome plays in human disease. By building this selective set of compounds and making it freely available, UNC-Chapel Hill and its partners are offering the and the ability to collaborate on the discovery and advancement of new therapies.

“Through our collaboration with DiscoverX, we screened a large set of compounds that we call Published Kinase Inhibitor Set 2, and these results allowed us to reach the halfway point in constructing the KCGS” explained lead study investigator David Drewry, Ph.D., a research associate professor at the UNC Eshelman School of Pharmacy. “To mark this milestone and in keeping with our mission of open science, we are releasing these results into the public domain. We sincerely thank all of our co-author partners whose vision, generosity and hard work make the construction of this set possible.”

The kinome, made up of enzymes called kinases, provides a tremendous opportunity for drug discovery. While more than 30 kinase inhibitors have been approved for the treatment of disease, the kinome has been largely unexplored until SGC-UNC, DiscoverX and other SGC partner companies embarked on this project. Findings from the new study also contain the results of screening each compound in PKIS2 against the DiscoverX panel of more than 400 kinase assays.

PKIS2 is a collection of more than 500 kinase inhibitors donated by GSK, Pfizer, and Takeda Pharmaceuticals that SGC-UNC makes available to the scientific community. The kinome wide annotation of inhibition profiles allows users of the set to interpret their results more readily.

“We have shown how well each of the PKIS2 compounds inhibits each of the kinases DiscoverX screens,” Dr. Drewry noted. “Researchers to whom we have given access to PKIS2 can use that information. They will know that compound X inhibits kinases A, B, and C, but compound Z inhibits kinases D, and E. With such a big data set people can easily find compounds of particular interest to them and know that the compounds are annotated with near full-kinome inhibition data.”

This collaborative project between industrial and academic scientists will continue to expand the KCGS with the goal of fully covering all human protein kinases. Dr. Drewry and his fellow scientists aim to ensure the therapeutic potential of as many protein kinases as possible will be uncovered. The expansion of the KCGS, combined with its use in diverse disease-relevant phenotypic screens and the sharing of the resulting data in the public domain, is the best mechanism for reaching this goal.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

02
Peptide Therapy Guide Editorial Team

Bayer, X-Chem Expand Drug Discovery Collaboration

Bayer and X-Chem Pharmaceuticals have expanded a global drug discovery collaboration launched in 2012 across multiple therapeutic areas and target classes. The expanded partnership could generate up to $528 mi…

Read guide →